scale average bioequivalence for parallel design [RSABE / ABEL]

posted by Mahmoud  – Jordan, 2022-06-15 12:33 (22 d 06:27 ago) – Posting: # 23059
Views: 260

Dear All
In the following paper

Statistical methodology for highly variable compounds: A novel design approach for the Ofatumumab Phase 2 bioequivalence study

Used scale average bioequivalence for parallel design

Is this method accepted by FDA and EMA


Edit: Category changed; see also this post #1[Helmut]

Complete thread:

UA Flag
 Admin contact
22,193 posts in 4,651 threads, 1,574 registered users;
online 8 (1 registered, 7 guests [including 6 identified bots]).
Forum time: Thursday 19:01 CEST (Europe/Vienna)

Any sufficiently advanced technology
is indistinguishable from magic.    Arthur C. Clarke

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz